Destiny Pharma plc (“Destiny Pharma” or the “Company”) Interim results for the six months ended 30 June 2018 Clinical progress and pipeline expansion in dermal infections; well-funded through to H2 2020 Brighton, United Kingdom – 26 September 2018 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development […]
Destiny Pharma plc (“Destiny” or “the Company”) Dr Jesús González brings extensive experience in the clinical development of anti-infectives, as the Company prepares to initiate a Phase 2b trial for lead asset Brighton, United Kingdom – 26 September 2018 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel antimicrobial […]
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Brighton, United Kingdom – 6 September 2018 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, which address the global problem of antimicrobial resistance (AMR), announces that Sir Nigel Rudd is stepping down as Chairman and a member of […]
Positive data supports product opportunities for XF-73 in dermal infection indications Data also supports planned Phase 2 clinical trial of XF-73 nasal gel for the prevention of post-surgical infection Brighton, United Kingdom – 26 July 2018 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, which address the […]
Research to investigate potential antimicrobial candidates against biofilms Brighton, United Kingdom – 17 July 2018 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, which address the global problem of antimicrobial resistance (AMR), today announces it has signed a three-year research collaboration agreement with Aston University. The […]
Brighton, United Kingdom – 14 June 2018 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel anti-microbial drugs, which address the global problem of anti-microbial resistance (AMR), notes the FDA Commissioner, Scott Gottlieb M.D.’s further announcements this week outlining the regulator’s support of new incentives for companies developing novel […]
Destiny Pharma has a Scientific Advisory Board (SAB) of key opinion leaders in relevant fields to help guide and inform the future clinical development of the XF platform. Our SAB includes the following members: David Roblin MD FRCP FFPM FMedSci (SAB Chairman) Professor David Roblin is President of Research and Development at Summit Therapeutics. David […]
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Destiny Pharma plc (“Destiny Pharma” or “the company”) Destiny Pharma […]
Posted on 15/03/2018 THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Destiny Pharma plc (“Destiny Pharma” or “the Company”) […]
Posted on 05/02/2018 Destiny Pharma has won Deal of the Year at the Insider South East Dealmakers Awards 2018, held on 1 February 2018 at The Copthorne in Gatwick, UK. Now in its twelfth year, the Dealmakers awards recognise the region’s top deals and advisory companies over the course of the last 12 months. The Deal […]